Business Context and Reporting Period
Spyre Therapeutics, Inc. (Nasdaq: SYRE) filed a Current Report on Form 8-K on December 7, 2023. The filing details the entry into a Material Definitive Agreement for a private placement of equity securities with institutional and accredited investors. The transaction is expected to close on December 11, 2023.
Key Financial Metrics and Transaction Details
The Company entered into a Securities Purchase Agreement to raise approximately $180.0 million. The capital raise consists of:
- Common Stock: 6,000,000 shares at $15.00 per share.
- Series B Preferred Stock: 150,000 shares of Series B Non-Voting Convertible Preferred Stock at $600.00 per share.
Each share of Series B Preferred Stock is convertible into 40 shares of Common Stock. The filing does not provide specific revenue, profit, cash flow, or debt metrics for the reporting period, as this is a transactional filing rather than a periodic financial report.
Material Changes and Capital Structure
Following the closing of the private placement, the Company expects the following capital structure changes:
- Post-Closing Common Stock: Approximately 36,021,007 shares issued and outstanding.
- Pro Forma Common Stock: Approximately 59.8 million shares issued and outstanding, assuming full conversion of Series A and Series B Preferred Stock and the exercise of all outstanding pre-funded warrants.
The Company filed a Certificate of Designation for the Series B Preferred Stock, which grants dividend rights on an as-if-converted basis but no voting rights, except for specific protective provisions regarding amendments to charter documents.
Guidance, Outlook, and Management Commentary
The filing does not contain forward-looking financial guidance or management commentary regarding operational performance. Key procedural commitments include:
- Stockholder Approval: The Company must submit a proposal to stockholders at its 2024 annual meeting to approve the conversion of Series B Preferred Stock into Common Stock, as required by Nasdaq rules.
- Registration Rights: The Company must file a registration statement within 30 days of the Closing Date and use commercially reasonable efforts to have it declared effective within 90 days.
- Placement Agents: Jefferies LLC, Cowen and Company, LLC, Stifel, Nicolaus & Company, Incorporated, Guggenheim Securities, LLC, and LifeSci Capital LLC were engaged as placement agents.
Investor Verification Checklist
- Verify the final closing date and confirmation of the $180.0 million aggregate purchase price.
- Confirm the outcome of the stockholder vote at the 2024 annual meeting regarding the conversion of Series B Preferred Stock.
- Review the filed Certificate of Designation (Exhibit 3.1) for specific limitations on beneficial ownership percentages (0% to 19.9%) that may restrict conversion.
- Monitor the filing and effectiveness of the registration statement for the resale of securities within the mandated 30 and 90-day windows.
- Assess the impact of the pro forma share count (approx. 59.8 million) on existing shareholder dilution.